Lack of association between IRF5 gene polymorphisms and biopsy-proven giant cell arteritis

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 136-140

  Torres, Orlando ^a   Palomino Morales, Rogelio ^a   Vazquez Rodriguez, Tomas R ^f   Castañeda, Santos ^e   Morado, Inmaculada C ^d   Miranda Filloy, Jose A ^f   Valero, Fernando ^b   Callejas Rubio, Jose L ^c   Fernandez Gutierrez, Benjamin ^d   Martin, Javier ^a   Gonzalez Gay, Miguel A ^f  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f HOSPITAL XERAL CALDE   (Spain)

Author keywords

Disease susceptibility; Gene polymorphism; Genetic studies; Giant cell arteritis; IRF5

Indexed keywords

CORTICOSTEROID; DNA; INTERFERON REGULATORY FACTOR 5;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL BIOPSY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GIANT CELL ARTERITIS; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA;

AGED; AGED, 80 AND OVER; BIOPSY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GIANT CELL ARTERITIS; HUMANS; INTERFERON REGULATORY FACTORS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 73649099453     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090744     Document Type: Article

References (20)

1. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Fillow JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009;61:1454-61.
2. Weyand CM, Goronzy JJ. Giant cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003;139:505-15.
3. Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Gorozny JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997;40:19-26.
4. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003;33:38-48.
5. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Amoli MM, Llorca J, et al. Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004;22 Suppl 36:S18-20.
6. Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002;22:5721-40.
7. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001;276:23382-90.
8. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005;76:528-37.
9. Sigurdsson S, Göring HH, Kristjansdottir G, Milani L, Nordmark G, Sandling JK, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008;17:872-81.
10. Han SW, Lee WK, Kwon KT, Lee BK, Nam EJ, Kim GW. Association of polymorphisms in interferon regulatory factor 5 gene with rheumatoid arthritis: a metaanalysis. J Rheumatol 2009;36:693-7.
11. Rueda B, Reddy MV, González-Gay MA, Balsa A, Pascual-Salcedo D, Petersson IF, et al. Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis. Arthritis Rheum 2006;54:3815-9.
12. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001;30:249-56.
13. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R, Lopez-Diaz MJ, Vazquez-Trinanes MC, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009;88:227-35.
14. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Peña-Sagredo JL, Martin J, Gonzalez-Gay MA. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum 2008;38:116-23.
15. Gonzalez-Gay MA, García-Porrúa C, Vázquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998;25:1750-5. Erratum in: J Rheumatol 1998;25:2483.
16. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, Garcia-Porrua C, Sanchez-Andrade A, Paz-Carreira J, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005;84:277-90.
17. Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004;83:342-7.
18. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
19. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Mattey DL, Amoli MM, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002;20:179-84.
20. Martin J, Perez-Armengol C, Miranda-Filloy JA, Vilchez JR, Lopez-Nevot MA, Garcia-Porrua C, et al. Lack of association of a functional -94ins/del ATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain. J Rheumatol 2006;33:285-8.